AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03578783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing.
Trial: NCT03578783
Drug: PSD502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing.
Trial: NCT00242840
Drug: No intervention; Observational study
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01447147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules once daily
Trial: NCT01447147
Drug: CCX140-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX140-B capsules once daily (Group B)
Trial: NCT01447147
Drug: CCX140-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX140-B capsules once daily (Group C)
Trial: NCT01471652
Drug: Nutraceutical supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. CoEnzyme Q10: oral gel capsule bid~2. Acetyl L-carnitine: oral capsule bid~3. Alpha Lipoic Acid: oral tablet qd~4. Docosahexaenoic acid: oral gel capsule bid
Trial: NCT01471652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule form to imitate the following nutraceuticals:~1. Placebo 1: oral gel capsule bid~2. Placebo 2: oral capsule bid~3. Placebo 3: oral tablet qd~4. Placebo 4: oral gel capsule bid
Trial: NCT04904952
Drug: N-acetylcysteine tablet 600mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
Trial: NCT04904952
Drug: Placebo tablet 600mg
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet 600mg/day and doubling weekly to reach a maximum dose of 2400mg/day (at week-3) for remaining 7 weeks along with SSRIs
Trial: NCT02190162
Drug: Tantum Verde® mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01377103
Drug: testerone gel
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
Trial: NCT01377103
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01367990
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The occipital scalp zone at risk for alopecia will be identified. The norepinephrine treatment site will be randomized to receive consistent treatment of one half of the scalp risk zone. Approximately 1.6 mL of a 400 mM norepinephrine solution will be applied topically to the norepinephrine site approximately 20 minutes prior to each radiation treatment, and placebo will be applied to the contralateral side (30-35 treatments).
Trial: NCT03623529
Drug: LJPC-501 (angiotensin II)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.
Trial: NCT03623529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Arm
Trial: NCT00030732
Drug: Gemcitabine + Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine + Capecitabine
Trial: NCT03752437
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 IU of heparin
Trial: NCT02212951
Drug: BIOD-531
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02212951
Drug: Humalog Mix 75/25
RxNorm normalized name: HumaLOG Mix 75/25
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02873351
Drug: carbidopa-levodopa 25-100 mg
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: included in arm description
Trial: NCT02873351
Drug: placebo for carbidopa-levodopa 25-100 mg
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: included in arm description
Trial: NCT02578706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02231905
Drug: BI-Sifrol®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02961829
Drug: Sirtuin Histone deacetylase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: latency disruption
Trial: NCT00087867
Drug: SCIO-469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 30-mg capsules three times daily
Trial: NCT00622440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 48 weeks.
Trial: NCT05125588
Drug: Reumoxicam® 15 mg tablets (PJSC Farmak, Ukraine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
Trial: NCT00545259
Drug: AEB071
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04277338
Drug: SPECT
RxNorm normalized name: Spectrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One single injection of 99mTc-HE3-G3, followed by gamma camera imaging directly postinjection and after 2, 4, 6 and 24 hours.
Trial: NCT01082068
Drug: XL147 (SAR245408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given orally once daily as tablets
Trial: NCT01042106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2.5, 10, 20, 40 mg orally once daily
Trial: NCT00196313
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet daily by mouth
Trial: NCT03760042
Drug: Within-Subject Active vs Placebo Topical Applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole 2% ointment (right side) and Placebo vehicle ointment (left side)
Trial: NCT03760042
Drug: Within-Subject Active vs. Placebo Topical Applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crisaborole 2% ointment (left side) and Placebo vehicle ointment (right side)
Trial: NCT01664260
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
Trial: NCT00560170
Drug: Simvastatin (Zocor)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg of Simvastatin (n=20) orally per-day for 28 days
Trial: NCT00560170
Drug: 10mg/10mg of Ezetimibe/Simvastatin (Vytorin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
Trial: NCT00010634
Drug: Connective Tissue Nutrient Formula
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03199989
Drug: CapeOX（Capecitabine+Oxaliplatin）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months
Trial: NCT02660372
Drug: Imonogas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone 120 mg in gel capsules
Trial: NCT02660372
Drug: Espumisan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simethicone 40 mg in gel capsules
Trial: NCT00647959
Drug: Doxycycline Tablets, 150mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg, single dose fasting
Trial: NCT00647959
Drug: Adoxa Tablets 150 mg
RxNorm normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg, single dose fasting
Trial: NCT03210337
Drug: A-101 Topical Solution
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-101 Topical Solution
Trial: NCT01821391
Drug: NDL-PDT
RxNorm normalized name: SYRINGE 1ML/NDL 20G 1IN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metvix natural daylight photodynamic therapy
Trial: NCT01258686
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700mg thrice daily
Trial: NCT01258686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 700mg thrice daily
Trial: NCT01821391
Drug: c-PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metvix conventional photodynamic therapy
Trial: NCT01821391
Drug: placebo c-PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metvix placebo conventional photodynamic therapy
Trial: NCT03350672
Drug: FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in cohorts 1a\&b will be administered FTC/TAF for 1 to 7 consecutive days and then be followed clinically for 6 to 14 days. Cohort 2 will participate in a 1 time blood and urine collection.
Trial: NCT02481219
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01354314
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule in the morning, three capsules in the evening
Trial: NCT00414336
Drug: AMA1-C1/Alhydrogel + CPG 7909 Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02044094
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for hydromorphone administered via intramuscular injection during each challenge.
Trial: NCT01740648
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.
Trial: NCT02321709
Drug: SAR113244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Trial: NCT02321709
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution for injection Route of administration: subcutaneous
Trial: NCT01809340
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).
Trial: NCT01809340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.
Trial: NCT00783107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01871935
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anaesthesia with remifentanil/propofol.
Trial: NCT01871935
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anaesthesia with sufentanil/propofol
Trial: NCT04472910
Drug: Modified Folforinox (mFFX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neo-adjuvant mFFX for up to 6 cycles, chemo-Adjuvant FFX q 2 weekly or other approach as per investigator to complete up to 6 months chemotherapy
Trial: NCT03854799
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible patients will receive:~CHEMORADIOTHERAPY PLUS AVELUMAB:~* CAPECITABINE 825 mg/sqm/bid p.o. 5 days/week~* EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 fractions over 5.5 weeks~* AVELUMAB 10 mg/Kg ev over 1 hour every 2 weeks at days 1, 14, 28, 42, 56, 70~Surgery with TME must be performed at week 8-10 after the end of CTRT. The final choice of surgical procedure (ie, abdominoperineal surgery or anterior resection) is at the surgeon's discretion.
Trial: NCT03899922
Drug: Drugs inducing uveitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs susceptible to induce uveitis
Trial: NCT01730482
Drug: [14C] AT1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of \[14C\] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
Trial: NCT00040326
Drug: antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pharmacotherapy
Trial: NCT01149018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
Trial: NCT00201630
Drug: Uroxatrol (drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02322866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching sarecycline tablets, taken orally at the same time each day.
Trial: NCT00467753
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
Trial: NCT00734877
Drug: M-VTD-PACE
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
Trial: NCT00734877
Drug: TT3-LITE Regimen (L-TT3)
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD-PACE and, as in S-TT3, PBSC collection following recovery from this one and only induction treatment. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying fractionated MEL200mg/m2 in 4 successive daily fractions of 50mg/m2 (MEL50 x 4) with addition of VTD with adjustments for age and renal function. Consolidation will consist of only 1 cycle of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
Trial: NCT03186742
Drug: Eplerenone 50 mg Tab
RxNorm normalized name: eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone 50 mg Tab once a day
Trial: NCT00416221
Drug: Lexapro, an antidepressant medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02037230
Drug: MK-1775
RxNorm normalized name: vitamin MK 7
DrugBank: Vitamin K7 (DB15664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .
Trial: NCT03581500
Drug: Hyperpolarized Carbon C 13 Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02384200
Drug: gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV (5 mg/kg)
Trial: NCT03374709
Drug: Oxtellar XR 150Mg Extended Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxtellar XR
Trial: NCT01258010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
Trial: NCT02817464
Drug: TV-46046 - 400 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single subcutaneous injection in the abdomen of undiluted TV-46046 - 400 mg/mL
Trial: NCT02817464
Drug: TV-46046 - 200 mg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single subcutaneous injection in the abdomen of saline-diluted TV-46046 - 200 mg/mL
Trial: NCT02731105
Drug: Acnatac® Gel left face
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application
Trial: NCT02731105
Drug: Epiduo® Gel right face
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application
Trial: NCT02731105
Drug: Acnatac® Gel right face
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application
Trial: NCT02731105
Drug: Epiduo® Gel left face
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application
Trial: NCT01683786
Drug: Pegintron + Riba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800\~1400 mg/day
Trial: NCT03193593
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo- Single injection of saline into Pectoralis Muscle
Trial: NCT00924313
Drug: (C-11 Acetate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
Trial: NCT03005717
Drug: LIPO-202
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03005717
Drug: Placebo for LIPO-202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophile manufactured to mimic LIPO-202 lyophile.
Trial: NCT05428306
Drug: A1: Ibuprofen/Acetaminophen Fixed dose combination (Laboratorios Silanes S.A. de C.V.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula : 200 mg/ 500 mg Pharmaceutical Form: Tablet Dosage: 400 mg / 1000 mg (2 tablets) Administration way: oral
Trial: NCT05428306
Drug: A2: Ibuprofen (Motrin®, Pfizer S.A. de C.V.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A2: Pharmaceutical Form: tablet Dosage: 400 mg (1 tablet) Administration way: oral
Trial: NCT05428306
Drug: A3: Acetaminophen (Tylenol caplets®, from Janssen-Cilag, S.A. de C.V.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A3:Pharmaceutical Form: tablet Formula: Acetaminophen 500 mg Dosage: 1000 mg (2 tablets) Administration way: oral
Trial: NCT01521793
Drug: QLT091001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral QLT091001 administered once daily for 7 days
Trial: NCT03507569
Drug: RO7017773
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7017773 will be administered orally. The doses to be tested will be determined by review of PET scan, PK, and safety results from the previous dose level.
Trial: NCT04427618
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 10ml normal saline (placebo) given within approximately 10 minutes before skin incision
Trial: NCT01322061
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
Trial: NCT00607373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
Trial: NCT02695420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT00983658
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT00556504
Drug: TCM-700C
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An add-on drug to conventional treatment of Hepatitis C
Trial: NCT00556504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, without acting ingredient.
Trial: NCT00705549
Drug: Pemetrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexate I.V 500mg/m2 on Day 1
Trial: NCT00457457
Drug: UK-369,003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (\>80 fold) compared to sildenafil (\~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
Trial: NCT02970942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily administration subcutaneously ( s.c., under the skin)
Trial: NCT00594581
Drug: Juvista (avotermin) plus placebo, standard-care (within-subject controls)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
Trial: NCT01495806
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glucose 5 g